249 related articles for article (PubMed ID: 37432459)
1. CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate.
Mungra N; Biteghe FAN; Malindi Z; Huysamen AM; Karaan M; Hardcastle NS; Bunjun R; Chetty S; Naran K; Lang D; Richter W; Hunter R; Barth S
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12203-12225. PubMed ID: 37432459
[TBL] [Abstract][Full Text] [Related]
2. The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.
Woitok M; Klose D; Niesen J; Richter W; Abbas M; Stein C; Fendel R; Bialon M; Püttmann C; Fischer R; Barth S; Kolberg K
Cancer Lett; 2016 Oct; 381(2):323-30. PubMed ID: 27502168
[TBL] [Abstract][Full Text] [Related]
3. EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment.
Zhang C; Sheng W; Al-Rawe M; Mohiuddin TM; Niebert M; Zeppernick F; Meihold-Heerlein I; Hussain AF
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682800
[TBL] [Abstract][Full Text] [Related]
4. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
[TBL] [Abstract][Full Text] [Related]
5. Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells.
Woitok M; Klose D; Di Fiore S; Richter W; Stein C; Gresch G; Grieger E; Barth S; Fischer R; Kolberg K; Niesen J
Onco Targets Ther; 2017; 10():3313-3327. PubMed ID: 28740407
[TBL] [Abstract][Full Text] [Related]
6. Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand.
Amoury M; Bauerschlag D; Zeppernick F; von Felbert V; Berges N; Di Fiore S; Mintert I; Bleilevens A; Maass N; Bräutigam K; Meinhold-Heerlein I; Stickeler E; Barth S; Fischer R; Hussain AF
Oncotarget; 2016 Aug; 7(34):54925-54936. PubMed ID: 27448975
[TBL] [Abstract][Full Text] [Related]
7. Click Chemistry-Generated Auristatin F-Linker-Benzylguanine for a SNAP-Tag-Based Recombinant Antibody-Drug Conjugate Demonstrating Selective Cytotoxicity toward EGFR-Overexpressing Tumor Cells.
Huysamen AM; Fadeyi OE; Mayuni G; Dogbey DM; Mungra N; Biteghe FAN; Hardcastle N; Ramamurthy D; Akinrinmade OA; Naran K; Cooper S; Lang D; Richter W; Hunter R; Barth S
ACS Omega; 2023 Jan; 8(4):4026-4037. PubMed ID: 36743041
[TBL] [Abstract][Full Text] [Related]
8. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
[TBL] [Abstract][Full Text] [Related]
9.
Kasten BB; Oliver PG; Kim H; Fan J; Ferrone S; Zinn KR; Buchsbaum DJ
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29561763
[TBL] [Abstract][Full Text] [Related]
10. One-step site-specific antibody fragment auto-conjugation using SNAP-tag technology.
Hussain AF; Heppenstall PA; Kampmeier F; Meinhold-Heerlein I; Barth S
Nat Protoc; 2019 Nov; 14(11):3101-3125. PubMed ID: 31605098
[TBL] [Abstract][Full Text] [Related]
11. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.
Eng MS; Kaur J; Prasmickaite L; Engesæter BØ; Weyergang A; Skarpen E; Berg K; Rosenblum MG; Mælandsmo GM; Høgset A; Ferrone S; Selbo PK
Photochem Photobiol Sci; 2018 May; 17(5):539-551. PubMed ID: 29565434
[TBL] [Abstract][Full Text] [Related]
12. A new immunochemical strategy for triple-negative breast cancer therapy.
Lin CW; Zheng T; Grande G; Nanna AR; Rader C; Lerner RA
Sci Rep; 2021 Jul; 11(1):14875. PubMed ID: 34290315
[TBL] [Abstract][Full Text] [Related]
13. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
[TBL] [Abstract][Full Text] [Related]
14. A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo.
Guo P; Huang J; Zhu B; Huang AC; Jiang L; Fang J; Moses MA
Sci Adv; 2023 May; 9(18):eabq7866. PubMed ID: 37146146
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells.
Khandelwal S; Boylan M; Spallholz JE; Gollahon L
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373175
[TBL] [Abstract][Full Text] [Related]
16. Applications of SNAP-tag technology in skin cancer therapy.
Padayachee ER; Adeola HA; Van Wyk JC; Nsole Biteghe FA; Chetty S; Khumalo NP; Barth S
Health Sci Rep; 2019 Feb; 2(2):e103. PubMed ID: 30809593
[TBL] [Abstract][Full Text] [Related]
17. Selection of novel affinity-matured human chondroitin sulfate proteoglycan 4 antibody fragments by yeast display.
Yu X; Qu L; Bigner DD; Chandramohan V
Protein Eng Des Sel; 2017 Sep; 30(9):639-647. PubMed ID: 28981720
[TBL] [Abstract][Full Text] [Related]
18. Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer.
Montero JC; Calvo-Jiménez E; Del Carmen S; Abad M; Ocaña A; Pandiella A
J Exp Clin Cancer Res; 2022 Mar; 41(1):106. PubMed ID: 35317825
[TBL] [Abstract][Full Text] [Related]
19. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
[TBL] [Abstract][Full Text] [Related]
20. A novel ADC targeting cell surface fibromodulin in a mouse model of triple-negative breast cancer.
Haji Ghaffari M; Simonian M; Salimi A; Mirzadegan E; Sadeghi N; Nejadmoghaddam MR; Ebrahimnezhad N; Fazli G; Fatemi R; Bayat AA; Mazloomi M; Rabbani H
Breast Cancer; 2022 Nov; 29(6):1121-1132. PubMed ID: 35982394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
